Previous close | 19.86 |
Open | 20.00 |
Bid | 19.90 x 900 |
Ask | 19.94 x 900 |
Day's range | 19.77 - 20.01 |
52-week range | 13.01 - 20.01 |
Volume | |
Avg. volume | 989,451 |
Market cap | 3.227B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 9.05 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.92 (9.67%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Hercules Capital ( NYSE:HTGC ) First Quarter 2024 Results Key Financial Results Revenue: US$121.6m (up 16% from 1Q...
Hercules Capital (HTGC) records y/y increases in total investment income and expenses in the first quarter of 2024.